Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours.
about
Response of estrogen receptor-positive breast cancer tumorspheres to antiestrogen treatmentsPhenotype anchoring in zebrafish reveals a potential role for matrix metalloproteinases (MMPs) in tamoxifen's effects on skin epithelium.Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators.Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent mannerLinking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosisUse of tamoxifen before and during pregnancyOxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies.Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancerSpatio-temporal analysis of tamoxifen-induced bystander effects in breast cancer cells using microfluidicsTamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug responsePregnancy on tamoxifen: Case-report and review of literature.Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometryMnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen.Clinical effects of A4889G and T6235C polymorphisms in cytochrome P-450 CYP1A1 for breast cancer patients treated with tamoxifen: implications for tumor aggressiveness and patient survival.Determination of tamoxifen and its metabolites in human plasma by nonaqueous capillary electrophoresis with contactless conductivity detection.
P2860
Q28477774-BC517209-9A50-40BA-862B-9C85FA977B2FQ30727473-5E4DBDC8-9D14-4F25-9FCD-1D5D036DF56FQ33576459-9A9FE40C-491D-42BF-AE17-D4524F6487B6Q33746249-19E180B2-0D2C-4188-AE5A-CF226A3B9142Q34736075-4174DFB6-73D4-4DA0-9908-2112E6F130DCQ34793924-B632642C-0020-48B0-A418-5F7F1DA1A1DCQ35599785-91773491-D319-4BE5-80C3-E7CBC0B2CE6EQ35608859-7D794956-B7C8-41B0-97D4-99EC9E0FB592Q35749331-D94B6096-AC4E-44CD-A333-172851949E8FQ36056035-9AFEA068-9E25-43CD-9404-FDFD1043B135Q36946542-874672A1-D22B-4104-99F4-E76618C5E3D7Q37532325-FDC5E706-62BE-4047-88DE-AFEC77FBA3C0Q37597968-91EBB198-D4E5-43B1-B818-F9F25353A0E7Q42706074-E75D973D-15CC-472B-90B2-F46802982483Q48031154-59E820AD-6098-440B-8FBB-686DDA76E87AQ53183265-11E38C39-5148-4E2B-8282-FF2F63581B65
P2860
Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Concentrations of tamoxifen an ...... and resistant breast tumours.
@ast
Concentrations of tamoxifen an ...... and resistant breast tumours.
@en
type
label
Concentrations of tamoxifen an ...... and resistant breast tumours.
@ast
Concentrations of tamoxifen an ...... and resistant breast tumours.
@en
prefLabel
Concentrations of tamoxifen an ...... and resistant breast tumours.
@ast
Concentrations of tamoxifen an ...... and resistant breast tumours.
@en
P2093
P2860
P356
P1476
Concentrations of tamoxifen an ...... and resistant breast tumours.
@en
P2093
P2860
P2888
P304
P356
10.1054/BJOC.2000.1120
P407
P577
2000-05-01T00:00:00Z
P5875
P6179
1043222793